For the quarter ending 2025-09-30, BTAI made $98,000 in revenue. -$30,911,000 in net income. Net profit margin of -31541.84%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Product revenue, net | 98,000 | 120,000 | 168,000 | 474,000 |
| Cost of goods sold | 11,000 | 107,000 | 14,000 | 455,500 |
| Research and development | 8,740,000 | 10,256,000 | 4,554,000 | 8,651,000 |
| Selling, general and administrative | 5,381,000 | 5,609,000 | 5,699,000 | 8,679,500 |
| Restructuring costs | 194,000 | 0 | - | 16,000 |
| Total operating expenses | 14,326,000 | 15,972,000 | 10,267,000 | 17,802,000 |
| Loss from operations | -14,228,000 | -15,852,000 | -10,099,000 | -17,328,000 |
| Interest expense | 4,373,000 | 4,222,000 | 3,993,000 | 3,819,500 |
| Interest income | 236,000 | 230,000 | 279,000 | 657,500 |
| Other (income) expense, net | -12,546,000 | 657,000 | 6,559,000 | 1,665,000 |
| Net loss | -30,911,000 | -19,187,000 | -7,254,000 | -18,825,000 |
| Earnings per share, basic | -2.18 | -2.45 | -1.5 | -11.49 |
| Earnings per share, diluted | -2.18 | -2.45 | -1.5 | -11.49 |
| Weighted average number of shares outstanding, basic | 14,196,000 | 7,843,000 | 4,834,000 | -40,054,000 |
| Weighted average number of shares outstanding, diluted | 14,196,000 | 7,843,000 | 4,834,000 | -40,054,000 |
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)